JuliaGlade BenderMD

Clinical Trials

• Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors Start of enrollment: 2001 Oct 01

  Completed

  Phase 1

• Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas Start of enrollment: 2001 Feb 01

  Completed

  Phase 1

• Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma Start of enrollment: 2000 Nov 01

  Completed

  Phase 1

• Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia Start of enrollment: 2001 Apr 01

  Completed

  Phase 2

• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas Start of enrollment: 2001 Apr 01

  Completed

  Phase 1

• Bortezomib in Treating Children With Advanced Solid Tumors Start of enrollment: 2001 Nov 01

  Completed

  Phase 1

• Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia Start of enrollment: 2002 Aug 01

  Completed

  Phase 2

• Tipifarnib in Treating Young Patients With Refractory Leukemia Start of enrollment: 2001 Jun 01

  Completed

  Phase 1

• Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood Start of enrollment: 2002 May 01

  Completed

  Phase 2

• Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma Start of enrollment: 2002 Jun 01

  Terminated

  Phase 1

• Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors Start of enrollment: 2002 Nov 01

  Completed

  Phase 1

• Gefitinib in Treating Children With Refractory Solid Tumors Start of enrollment: 2002 Jun 01

  Completed

  Phase 1

• Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Start of enrollment: 2002 Dec 01

  Terminated

  Phase 1

• Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Start of enrollment: 2003 May 01

  Completed

  Phase 2

• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Start of enrollment: 2002 Sep 01

  Completed

  Phase 1

• Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation Start of enrollment: 2003 Feb 01

  Completed

  Phase 1

• Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors Start of enrollment: 2008 Jan 01

  Completed

  Phase 2

• Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors Start of enrollment: 2003 Oct 01

  Completed

  Phase 1

• Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma Start of enrollment: 2003 Dec 01

  Completed

  Phase 1

• Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2004 Feb 01

  Completed

  Phase 1

• Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia Start of enrollment: 2004 Jan 01

  Completed

  Phase 1

• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia Start of enrollment: 2004 Mar 01

  Completed

  Phase 1

• Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia Start of enrollment: 2004 Mar 01

  Completed

  Phase 1

• Bevacizumab in Treating Young Patients With Refractory Solid Tumors Start of enrollment: 2003 Dec 01

  Completed

  Phase 1

• Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia Start of enrollment: 2004 Jul 01

  Completed

  Phase 2

• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Start of enrollment: 2004 Oct 01

  Completed

  Phase 2

• Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2005 Feb 01

  Completed

  Phase 1, Phase 2

• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Start of enrollment: 2005 Mar 01

  Completed

  Phase 1

• Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes Start of enrollment: 2005 Mar 01

  Completed

  Phase 1

• Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors Start of enrollment: 2005 May 01

  Completed

  Phase 1

• Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Start of enrollment: 2005 Oct 01

  Completed

  Phase 1

• Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia Start of enrollment: 2005 Aug 01

  Completed

  Phase 1

• Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate Start of enrollment: 2006 Mar 01

  Completed

  Phase 1

• Ixabepilone in Treating Young Patients With Refractory Solid Tumors Start of enrollment: 2006 Apr 01

  Completed

  Phase 2

• Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma Start of enrollment: 2006 Jun 01

  Completed

  Phase 1

• Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Start of enrollment: 2006 Jun 01

  Completed

  Phase 1

• Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors Start of enrollment: 2004 Oct 01

  Completed

  Phase 2

• Sunitinib in Treating Young Patients With Refractory Solid Tumors Start of enrollment: 2006 Oct 01

  Completed

  Phase 1

• Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment Start of enrollment: 2007 Feb 01

  Withdrawn

  Phase 1

• A Study of Pemetrexed in Children With Recurrent Cancer Start of enrollment: 2007 Sep 01

  Completed

  Phase 2

• IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor Start of enrollment: 2008 Jan 01

  Completed

  Phase 1

• Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2008 Apr 01

  Completed

  Phase 1

• Evaluating Dactinomycin and Vincristine in Young Patients With Cancer Start of enrollment: 2008 Feb 01

  Completed

• Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2009 Jan 01

  Completed

  Phase 2

• Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment Start of enrollment: 2009 Apr 01

  Completed

  Phase 1

• N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma Start of enrollment: 2009 Dec 01

  Completed

  Phase 1

• Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial Start of enrollment: 2008 Jul 01

  Completed

• Pharmacokinetic Studies Participation Survey Start of enrollment: 2008 Sep 23

  Completed

• Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment Start of enrollment: 2009 Jun 01

  Completed

  Phase 1

• Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia Start of enrollment: 2009 Jun 01

  Terminated

  Phase 1

• Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Start of enrollment: 2009 Sep 21

  Completed

  Phase 1, Phase 2

• Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL Start of enrollment: 2010 Jun 01

  Terminated

  Phase 1, Phase 2

• Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Start of enrollment: 2009 Aug 01

  Completed

  Phase 1

• Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Start of enrollment: 2009 Sep 01

  Completed

  Phase 1

• Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Start of enrollment: 2010 Feb 01

  Completed

  Phase 1

• Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Start of enrollment: 2010 Mar 01

  Terminated

  Phase 1

• Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2010 Jun 01

  Completed

  Phase 1

• Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Start of enrollment: 2011 Feb 01

  Completed

  Phase 2

• INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Start of enrollment: 2010 Sep 01

  Completed

  Phase 1

• MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Start of enrollment: 2011 Jan 01

  Completed

  Phase 1

• Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2010 Dec 01

  Completed

  Phase 1

• Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Start of enrollment: 2011 May 01

  Completed

  Phase 1

• A Study Of Panobinostat In Children With Refractory Hematologic Malignancies Start of enrollment: 2011 Mar 01

  Completed

  Phase 1

• Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2011 Sep 01

  Completed

  Phase 1

• A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Start of enrollment: 2011 Dec 01

  Terminated

  Phase 1, Phase 2

• Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Start of enrollment: 2012 Jan 01

  Completed

  Phase 2

• Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors Start of enrollment: 2012 Feb 01

  Completed

  Phase 1

• Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Start of enrollment: 2013 Apr 29

  Completed

  Phase 1

• Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Start of enrollment: 2012 Jun 18

  Completed

  Phase 2

• Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2012 Nov 14

  Completed

  Phase 1

• Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2012 Oct 01

  Completed

  Phase 1

• MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Start of enrollment: 2013 Nov 01

  Completed

  Phase 1

• Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2013 Jan 31

  Completed

  Phase 1, Phase 2

• Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Start of enrollment: 2013 Sep 03

  Completed

  Phase 1

• Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2014 Jun 30

  Withdrawn

  Phase 2

• Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2014 Mar 28

  Completed

  Phase 1, Phase 2

• Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Start of enrollment: 2014 May 16

  Completed

  Phase 1, Phase 2

• VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01

  Completed

  Phase 1

• This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas Start of enrollment: 2014 Jul 31

  Completed

  Phase 1

• Parental Decision-Making for Children With Relapsed Neuroblastoma Start of enrollment: 2013 May 01

  Active, not recruiting

• Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Start of enrollment: 2015 Mar 30

  Completed

  Phase 1, Phase 2

• Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas Start of enrollment: 2015 Oct 30

  Active, not recruiting

  Phase 1

• MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors Start of enrollment: 2008 Sep 01

  Completed

  Phase 1

• Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Start of enrollment: 2015 Oct 12

  Completed

  Phase 2

• A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11

  Completed

  Phase 1

• Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options Start of enrollment: 2016 May 03

  Active, not recruiting

  Phase 1, Phase 2

• Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2017 Jan 06

  Completed

  Phase 1

• Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2017 May 25

  Withdrawn

  Phase 1

• Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2017 Feb 27

  Completed

  Phase 1

• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Start of enrollment: 2017 May 18

  Active, not recruiting

  Phase 2

• Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2017 Aug 15

  Active, not recruiting

  Phase 1

• Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Start of enrollment: 2018 Sep 09

  Active, not recruiting

  Phase 2

• Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Start of enrollment: 2018 Jan 31

  Active, not recruiting

  Phase 1, Phase 2

• Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma Start of enrollment: 2018 Jan 11

  Active, not recruiting

  Phase 1

• A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment Start of enrollment: 2021 Jun 09

  Recruiting

  Phase 1

• Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma Start of enrollment: 2019 Apr 30

  Active, not recruiting

  Phase 1

  Roles: Contact, Principal Investigator

• Pilot Study to Enable Electronic Laboratory Data Transfer From Participating Institutions to MediData/RAVE Start of enrollment: 2021 Aug 28

  Active, not recruiting

  Roles: Contact

• LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Start of enrollment: 2016 Nov 02

  Recruiting

  Phase 2, Phase 3

  Roles: Contact

• Olaparib With Ceralasertib in Recurrent Osteosarcoma Start of enrollment: 2020 Nov 24

  Recruiting

  Phase 2

  Roles: Contact, Principal Investigator

• A Study of Avutometinib for People With Solid Tumor Cancers Start of enrollment: 2023 Oct 20

  Recruiting

  Phase 1

  Roles: Contact

• Join now to see all